Apr. 17 at 12:42 AM
Kailera Therapeutics has priced its IPO at
$16.00 per share for 39,062,500 common shares, aiming to raise
$625.0 million in gross proceeds before underwriting discounts and offering expenses. The clinical-stage biotechnology company, focused on obesity treatments, expects its shares to begin trading on the Nasdaq Global Select Market on April 17, 2026, with the offering scheduled to close on April 20, 2026, subject to customary closing conditions.
The underwriters have a 30-day option to purchase up to 5,859,375 additional shares at the IPO price, less underwriting discounts and commissions. All shares in the offering are being sold by the company.
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, and Evercore ISI are serving as joint book-running managers, with William Blair acting as lead manager. The SEC declared effective the registration statement on Form S-1 (File No. 333-294690) on April 16, 2026. The company is headquartered in Waltham, Massachusetts.
$JPM $EVR $JEF